Poland Pharma and Healthcare Sector Report 2024-2025

Poland's healthcare and pharmaceutical industry is making significant strides, despite facing substantial challenges. The ongoing war in Ukraine, which followed the COVID-19 pandemic, has placed considerable pressure on the Polish healthcare system. Nevertheless, strategic investments and modernisation efforts are fostering positive developments. The healthcare and pharmaceutical retail sector is characterised by intense competition, with companies expanding their digital presence and retail networks. Leading firms, such as Neuca and Lux Med, are heavily investing in research and development to introduce innovative products and enhance efficiency. Polpharma, a major Polish manufacturer, is focusing on R&D for generic and biosimilar medicines. Despite market competition and regulatory hurdles, Poland's pharma and healthcare sector is set for sustained growth, propelled by technological advancements and strategic initiatives.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Poland. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Poland
• Crystallise the forces both driving and restraining this sector in Poland
• Ascertain Poland’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Poland.
• Build a clear picture of trends, output and consumption for specific sub-sectors